BioTime Aktie [WKN DE: A2PP89 / ISIN: US53566P1093]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu BioTime Inc Registered Shs

22.06.21		Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing (Businesswire)
17.06.21		Lineage Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem® (Businesswire)
16.06.21		Lineage Cell Therapeutics Announces Kevin L. Cook to Join as Chief Financial Officer (Businesswire)
15.06.21		Lineage Cell Therapeutics to Present at Raymond James 2021 Human Health Innovation Conference on June 22, 2021 (Businesswire)
09.06.21		Lineage Cell Therapeutics Set to Join Russell 3000® Index and Russell Microcap® Index (Businesswire)
01.06.21		Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated With OpRegen® RPE Cells (Businesswire)
13.05.21		Lineage Reports First Quarter 2021 Financial Results and Highlights Significant Progress With All Three Clinical Programs (Businesswire)
05.05.21		Lineage Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of Directors (Businesswire)
04.05.21		Lineage Cell Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021 (Businesswire)
03.05.21		OpRegen® Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic Atrophy (Businesswire)
26.04.21		Lineage to Present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021 (Businesswire)
22.04.21		Lineage Announces Appointment of Dr. Dipti Amin to Its Board of Directors (Businesswire)
20.04.21		Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform (Businesswire)
12.04.21		OpRegen® Data Update to Be Featured at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Christopher D. Riemann, MD (Businesswire)
29.03.21		Lineage Cell Therapeutics Announces Vitelliform Maculopathy Patient Treated With OpRegen® Under Named Patient Compassionate Use (Businesswire)
23.03.21		Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic Atrophy (Businesswire)
17.03.21		Lineage to Present at the Benzinga Global Biotech Small Cap Conference on March 24, 2021 (Businesswire)
11.03.21		Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update (Businesswire)
09.03.21		Ausblick: BioTime legt Zahlen zum jüngsten Quartal vor (finanzen.net)
08.03.21		Lineage Cell Therapeutics Raises $35.9 Million From Sales of Marketable Securities Holdings and an At-the-Market Equity Offering (Businesswire)
01.03.21		Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021 (Businesswire)
23.02.21		Lineage to Present at the Raymond James 42nd Annual Institutional Investors Conference on March 1, 2021 and the H.C. Wainwright Global Life Sciences Conference on March 9, 2021 (Businesswire)
16.02.21		Lineage to Host Virtual OPC1 Investor & Analyst Day on February 22, 2021 (Businesswire)
08.02.21		Lineage Enters Into Exclusive Agreement with Neurgain Technologies to Evaluate Novel Delivery System for OPC1 to Treat Spinal Cord Injury (Businesswire)
21.01.21		Lineage Posts Series of Webinars Highlighting Recent Progress With its Three Clinical-Stage Allogeneic Cell Transplant Programs (Businesswire)
21.01.21		PFE/BNTX Covid Jab Neutralizes UK Strain, Pura Vida Ups Stake In OCX, Woodcock Is Interim FDA Chief (RTTNews)
20.01.21		Lineage Cell Therapeutics Announces Change to Executive Team (Businesswire)
20.01.21		Pre-market Movers In Healthcare Sector: LCTX, DARE, SRNE, NOVN, HSTO… (RTTNews)
28.12.20		Lineage Cell Therapeutics Provides End of Year Shareholder Letter (Businesswire)
09.12.20		Lineage Cell Therapeutics to Present at the 13th Annual LD Micro Main Event Conference on December 14, 2020 (Businesswire)
08.12.20		Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for the Treatment of Spinal Cord Injury (Businesswire)
16.11.20		Lineage Cell Therapeutics Presents New OpRegen® Data for Dry AMD With GA at 2020 American Academy of Ophthalmology Annual Meeting (Businesswire)
15.11.20		Week Ahead In Pharma: FDA Decisions, Data Readouts (ADMP, EIGR, KZIA, AVRO…) (RTTNews)
13.11.20		Lineage Cell Therapeutics Proudly Supports Patients’ Access to Innovative Cell Therapy Treatments and Research Through Passage of Proposition 14 (Businesswire)
11.11.20		Lineage Cell Therapeutics Completes Patient Enrollment in Phase 1/2a Clinical Study of OpRegen® Cell Therapy for the Treatment of Dry Age-related Macular Degeneration (Businesswire)
04.11.20		Lineage Cell Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update (Businesswire)
03.11.20		Ausblick: BioTime stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
02.11.20		Lineage Cell Therapeutics to Host Expert Call Following OpRegen® Data Update at 2020 American Academy of Ophthalmology Meeting (Businesswire)
28.10.20		Lineage Cell Therapeutics to Report Third Quarter 2020 Financial Results and Provide Business Update on November 4, 2020 (Businesswire)
15.10.20		OpRegen Data Update to Be Featured in Presentation by Christopher D. Riemann, MD at 2020 American Academy of Ophthalmology Meeting (Businesswire)
13.10.20		Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer (Businesswire)
17.09.20		Lineage Cell Therapeutics to Present at FORCE Wealth Virtual Fireside Chat on September 23, 2020 (Businesswire)
10.09.20		Lineage Cell Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 and at Cantor Virtual Global Healthcare Conference on September 17, 2020 (Businesswire)
08.09.20		Lineage Cell Therapeutics Awarded Grant From Israel Innovation Authority for Development of a Bio-Retinal Patch for Treatment of Retinal Diseases in Partnership With Precise Bio (Businesswire)
31.08.20		Lineage Cell Therapeutics Receives $24.6 Million Payment From Juvenescence Ltd. (Businesswire)
25.08.20		Lineage Cell Therapeutics to Present at LD Micro 500 Investor Conference and Solebury Trout Zoomside Chat on September 1, 2020 (Businesswire)
06.08.20		Lineage Cell Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on All Clinical Programs (Businesswire)
05.08.20		Ausblick: BioTime informiert über die jüngsten Quartalsergebnisse (finanzen.net)
30.07.20		Lineage Cell Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020 (Businesswire)
06.07.20		Lineage Cell Therapeutics Announces Extension of OpRegen® Development Grant From Israel Innovation Authority (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

Nah an 100.000er Marke: Bitcoin, Dogecoin, Ethereum & Co. am Vormittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.11.2024 13:20
Kaufwert:	EUR
	Hinzufügen Speichern